{"product_id":"amgn-marketing-mix","title":"Amgen Inc. (AMGN): Marketing Mix Analysis [June-2026 Updated]","description":"\u003cp\u003eThis ready-made late-2025 Marketing Mix Analysis of Amgen Inc. gives you a practical, research-based view of how the business grows through biologics like Repatha, Prolia, Enbrel, Evenity, Tezspire, Xgeva, and Otezla, plus oncology, rare disease, biosimilars, and the MariTide obesity pipeline; how it reaches customers through the U.S., Europe, specialty, hospital, and pharmacy channels; how promotion is driven by scientific congresses, clinical trial readouts, HCP education, patient support, the FIFA World Cup 2026 biotech partnership, and the Amgen Foundation; and how premium pricing, rebates, biosimilar pressure, and the 2025 IRA Medicare price setting on Otezla shape margins, access, and market position.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eAmgen Inc. - Marketing Mix: Product\u003c\/h2\u003e\n\u003cp\u003eAmgen's product mix is built around \u003cstrong\u003e7\u003c\/strong\u003e anchor brands: Repatha, Prolia, Enbrel, Evenity, Tezspire, Xgeva, and Otezla. \u003cstrong\u003e6\u003c\/strong\u003e of those are injectable biologics and \u003cstrong\u003e1\u003c\/strong\u003e is an oral small molecule, which matters because the portfolio is built for chronic use, repeat dosing, and specialist prescribing.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eTherapeutic area\u003c\/th\u003e\n\u003cth\u003eKey product numbers\u003c\/th\u003e\n\u003cth\u003eU.S. approval year\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepatha\u003c\/td\u003e\n\u003ctd\u003eLipid lowering\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e140 mg\u003c\/strong\u003e every \u003cstrong\u003e2\u003c\/strong\u003e weeks or \u003cstrong\u003e420 mg\u003c\/strong\u003e monthly\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2015\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProlia\u003c\/td\u003e\n\u003ctd\u003eBone health\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e60 mg\u003c\/strong\u003e every \u003cstrong\u003e6\u003c\/strong\u003e months\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2010\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnbrel\u003c\/td\u003e\n\u003ctd\u003eInflammatory disease\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e50 mg\u003c\/strong\u003e weekly\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1998\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvenity\u003c\/td\u003e\n\u003ctd\u003eBone health\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e210 mg\u003c\/strong\u003e monthly for \u003cstrong\u003e12\u003c\/strong\u003e doses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2019\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTezspire\u003c\/td\u003e\n\u003ctd\u003eSevere asthma\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e210 mg\u003c\/strong\u003e every \u003cstrong\u003e4\u003c\/strong\u003e weeks\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2021\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXgeva\u003c\/td\u003e\n\u003ctd\u003eOncology and bone complications\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e120 mg\u003c\/strong\u003e every \u003cstrong\u003e4\u003c\/strong\u003e weeks\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2010\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOtezla\u003c\/td\u003e\n\u003ctd\u003ePsoriasis and psoriatic arthritis\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e30 mg\u003c\/strong\u003e twice daily\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2014\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTepezza\u003c\/td\u003e\n\u003ctd\u003eThyroid eye disease\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10 mg\/kg\u003c\/strong\u003e first infusion, then \u003cstrong\u003e20 mg\/kg\u003c\/strong\u003e for the next \u003cstrong\u003e7\u003c\/strong\u003e infusions; \u003cstrong\u003e8\u003c\/strong\u003e infusions total every \u003cstrong\u003e3\u003c\/strong\u003e weeks\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2020\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUplizna\u003c\/td\u003e\n\u003ctd\u003eNeuromyelitis optica spectrum disorder and generalized myasthenia gravis\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e300 mg\u003c\/strong\u003e on day \u003cstrong\u003e1\u003c\/strong\u003e and day \u003cstrong\u003e15\u003c\/strong\u003e, then every \u003cstrong\u003e6\u003c\/strong\u003e months\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2020\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKrystexxa\u003c\/td\u003e\n\u003ctd\u003eChronic refractory gout\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e8 mg\u003c\/strong\u003e every \u003cstrong\u003e2\u003c\/strong\u003e weeks\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2010\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMariTide\u003c\/td\u003e\n\u003ctd\u003eObesity pipeline asset\u003c\/td\u003e\n\u003ctd\u003ePhase \u003cstrong\u003e2\u003c\/strong\u003e; once-monthly dosing target\u003c\/td\u003e\n\u003ctd\u003ePhase \u003cstrong\u003e2\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eProlia and Xgeva both use denosumab, but the product design is different enough to serve two separate markets. Prolia uses \u003cstrong\u003e60 mg\u003c\/strong\u003e every \u003cstrong\u003e6\u003c\/strong\u003e months, while Xgeva uses \u003cstrong\u003e120 mg\u003c\/strong\u003e every \u003cstrong\u003e4\u003c\/strong\u003e weeks. That split lets Amgen sell the same molecule into osteoporosis and oncology-related bone disease.\u003c\/p\u003e\n\n\u003cp\u003eAmgen's rare-disease expansion got a major product lift from the Horizon Therapeutics acquisition, completed for \u003cstrong\u003e$27.8bn\u003c\/strong\u003e. The added portfolio includes Tepezza, Uplizna, and Krystexxa, which broaden the company beyond bone, inflammation, and cardiovascular care into specialty endocrinology, neurology, and immunology. Tepezza's \u003cstrong\u003e8\u003c\/strong\u003e-infusion regimen and Uplizna's \u003cstrong\u003e6\u003c\/strong\u003e-month maintenance interval are important because they show how Amgen designs around long-duration treatment rather than one-time use.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKyprolis\u003c\/li\u003e\n\u003cli\u003eBlincyto\u003c\/li\u003e\n\u003cli\u003eTepezza\u003c\/li\u003e\n\u003cli\u003eUplizna\u003c\/li\u003e\n\u003cli\u003eKrystexxa\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBiosimilars diversify the product base and reduce dependence on mature brands. Amgen's biosimilar lineup includes Amjevita, Kanjinti, Mvasi, Ogivri, and Ziextenzo. This matters because Enbrel faces U.S. biosimilar competition no earlier than \u003cstrong\u003e2029\u003c\/strong\u003e, so Amgen needs new products and biosimilars to offset erosion in older franchises.\u003c\/p\u003e\n\n\u003cp\u003eAmgen's product design is increasingly about convenience. Repatha gives patients a choice between \u003cstrong\u003e140 mg\u003c\/strong\u003e every \u003cstrong\u003e2\u003c\/strong\u003e weeks and \u003cstrong\u003e420 mg\u003c\/strong\u003e monthly. Prolia reduces treatment frequency to \u003cstrong\u003e2\u003c\/strong\u003e doses per year. Evenity compresses therapy into \u003cstrong\u003e12\u003c\/strong\u003e monthly doses. Tezspire runs on a \u003cstrong\u003e4\u003c\/strong\u003e-week cycle. Otezla is the main oral product at \u003cstrong\u003e30 mg\u003c\/strong\u003e twice daily, which makes it different from the rest of the portfolio and gives Amgen one non-injectable option in a biologics-heavy mix.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eAmgen Inc. - Marketing Mix: Place\u003c\/h2\u003e\n\u003cp\u003eAmgen sells across \u003cstrong\u003e3\u003c\/strong\u003e major geographic buckets: the \u003cstrong\u003eU.S.\u003c\/strong\u003e, \u003cstrong\u003eEurope\u003c\/strong\u003e, and \u003cstrong\u003eother markets\u003c\/strong\u003e. Its commercial footprint spans \u003cstrong\u003e100+\u003c\/strong\u003e countries and regions, which matters because specialty medicines need controlled distribution, reimbursement access, and reliable supply close to the point of care.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePlace element\u003c\/th\u003e\n\u003cth\u003eReal-life marker\u003c\/th\u003e\n\u003cth\u003ePlace impact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal sales footprint\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e regional buckets: U.S., Europe, other markets; \u003cstrong\u003e100+\u003c\/strong\u003e countries and regions\u003c\/td\u003e\n\u003ctd\u003eSupports region-specific pricing, reimbursement, and logistics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty pharmacy channel\u003c\/td\u003e\n\u003ctd\u003eSpecialty medicines routed through restricted dispensing paths\u003c\/td\u003e\n\u003ctd\u003eImproves control over inventory, refills, and patient support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital and physician-administered channel\u003c\/td\u003e\n\u003ctd\u003eHospital and office-based administration for certain products\u003c\/td\u003e\n\u003ctd\u003eRequires synchronized supply, scheduling, and cold-chain handling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect commercial teams\u003c\/td\u003e\n\u003ctd\u003eField teams work with physicians and payers\u003c\/td\u003e\n\u003ctd\u003eSupports formulary access, reimbursement, and adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient access support\u003c\/td\u003e\n\u003ctd\u003eAmgenNow\u003c\/td\u003e\n\u003ctd\u003eHelps patients move from prescription to therapy start\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply network\u003c\/td\u003e\n\u003ctd\u003eManufacturing and R\u0026amp;D presence in the U.S., Puerto Rico, Ireland, and Singapore\u003c\/td\u003e\n\u003ctd\u003eSupports launch readiness and continuity of supply\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eAmgen's place strategy depends heavily on specialty and hospital channels rather than mass retail. That matters because many of its products are biologics or other complex therapies that move through limited distribution networks, which reduces diversion risk and gives the company more control over product handling, inventory, and patient onboarding.\u003c\/p\u003e\n\n\u003cp\u003eDirect commercial teams support physicians and payers because access decisions often depend on formulary placement, prior authorization, step edits, and reimbursement approval. In practice, place is not just shipping product; it is also getting the medicine into the right channel so the patient can receive it without avoidable delay.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e100+\u003c\/strong\u003e countries and regions support a geographically broad access model.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e main sales buckets keep regional distribution and reimbursement organized.\u003c\/li\u003e\n\u003cli\u003eSpecialty pharmacy routes are central for self-administered therapies.\u003c\/li\u003e\n\u003cli\u003eHospital and physician-administered sites are central for infusion and office-based care.\u003c\/li\u003e\n\u003cli\u003eField teams work with physicians and payers to reduce access friction.\u003c\/li\u003e\n\u003cli\u003eAmgenNow supports patient access after the prescription is written.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAmgen's manufacturing and R\u0026amp;D footprint matters to place because supply has to match launch timing, regional demand, and channel requirements. A multi-site network in the U.S., Puerto Rico, Ireland, and Singapore helps reduce single-site dependency and gives the company more flexibility in supplying the U.S., Europe, and other markets.\u003c\/p\u003e\n\n\u003cp\u003eFor academic work, place in Amgen's marketing mix can be framed as a controlled-access distribution model: specialty pharmacy, hospital, physician, and payer channels are coordinated so the product can move from manufacturer to patient with fewer barriers.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eAmgen Inc. - Marketing Mix: Promotion\u003c\/h2\u003e\n\u003cp\u003eAmgen's promotion is built around scientific proof, physician education, patient access support, and reputation building. The company reported \u003cstrong\u003e$28.2B\u003c\/strong\u003e in total revenue in 2023, and the Amgen Foundation has donated more than \u003cstrong\u003e$400M\u003c\/strong\u003e since \u003cstrong\u003e1991\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePromotion channel\u003c\/th\u003e\n\u003cth\u003eReal-life reference point\u003c\/th\u003e\n\u003cth\u003eNumeric anchor\u003c\/th\u003e\n\u003cth\u003eBusiness effect\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScientific congresses\u003c\/td\u003e\n\u003ctd\u003eASCO, ASH, EHA, ESMO, AHA, ADA\u003c\/td\u003e\n\u003ctd\u003e2023 revenue: \u003cstrong\u003e$28.2B\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eTurns trial data into prescriber awareness and launch momentum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCP education\u003c\/td\u003e\n\u003ctd\u003eCongress symposia, peer-to-peer education, medical affairs content\u003c\/td\u003e\n\u003ctd\u003e2023 revenue: \u003cstrong\u003e$28.2B\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSupports specialty launches where physician knowledge drives use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient support\u003c\/td\u003e\n\u003ctd\u003eAccess help, reimbursement support, adherence tools\u003c\/td\u003e\n\u003ctd\u003eNo company-wide public count disclosed\u003c\/td\u003e\n\u003ctd\u003eReduces friction after prescription and supports continuation on therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorporate visibility\u003c\/td\u003e\n\u003ctd\u003ePublic sponsorship or partnership activity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNo verified public Amgen FIFA World Cup 2026 biotech partnership disclosed in available company materials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmgen Foundation\u003c\/td\u003e\n\u003ctd\u003eScience education and community support\u003c\/td\u003e\n\u003ctd\u003eSince \u003cstrong\u003e1991\u003c\/strong\u003e; more than \u003cstrong\u003e$400M\u003c\/strong\u003e donated\u003c\/td\u003e\n\u003ctd\u003eBuilds trust with scientists, educators, patients, and policymakers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eScientific congresses and clinical trial readouts drive awareness\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAmgen uses medical meetings such as ASCO, ASH, EHA, ESMO, AHA, and ADA to present clinical data to physicians, researchers, and payers. In biotech, this is a core promotion channel because the message is built on endpoint data, safety data, and label-expansion evidence rather than broad consumer advertising.\u003c\/p\u003e\n\u003cp\u003eThe scale of the company matters here. A business that produced \u003cstrong\u003e$28.2B\u003c\/strong\u003e in revenue in 2023 can keep returning to major congresses year after year, which helps convert scientific visibility into prescribing consideration.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eASCO for oncology readouts\u003c\/li\u003e\n\u003cli\u003eASH and EHA for hematology and blood cancer data\u003c\/li\u003e\n\u003cli\u003eESMO for European oncology visibility\u003c\/li\u003e\n\u003cli\u003eAHA for cardiovascular evidence\u003c\/li\u003e\n\u003cli\u003eADA for diabetes and metabolic data\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eHCP-focused education supports specialty launches\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAmgen's physician promotion relies on congress symposia, digital education, medical affairs teams, and peer-to-peer scientific exchange. This matters most for specialty therapies, where adoption depends on dosing, monitoring, safety, and reimbursement knowledge as much as on the clinical result itself.\u003c\/p\u003e\n\u003cp\u003eFor an academic analysis, this section shows how promotion in biopharma is tied to evidence distribution. The commercial message is usually the clinical data package, not a lifestyle campaign.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePatient support programs reinforce access and adherence\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAmgen's patient-facing promotion focuses on access help after the prescription is written. Reimbursement support, benefits verification, and adherence tools matter because specialty medicines often face insurance hurdles and discontinuation risk if the patient cannot start therapy quickly.\u003c\/p\u003e\n\u003cp\u003eThis part of promotion is important in market analysis because it links marketing to realized sales. A prescription only becomes revenue if the patient can obtain and stay on therapy.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFIFA World Cup 2026 biotech partnership boosts brand visibility\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo verified public Amgen partnership for the \u003cstrong\u003e2026\u003c\/strong\u003e FIFA World Cup was disclosed in available company materials, so it should not be treated as a factual promotion channel without a published agreement.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAmgen Foundation builds science and health reputation\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe Amgen Foundation supports the companys reputation through science education and community programs. Since \u003cstrong\u003e1991\u003c\/strong\u003e, it has donated more than \u003cstrong\u003e$400M\u003c\/strong\u003e, which gives Amgen a long-term public-interest profile beyond product sales.\u003c\/p\u003e\n\u003cp\u003eThat kind of giving matters strategically because it strengthens trust with schools, universities, health organizations, and public stakeholders, which supports the broader brand even when the company is not advertising a specific medicine.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eAmgen Inc. - Marketing Mix: Price\u003c\/h2\u003e\n\n\u003cp\u003eAmgen Inc. priced its 2025 portfolio around specialty-biologic premiums, but net realized price stayed under pressure from rebates, biosimilars, and Medicare rules. The clearest numerical markers are \u003cstrong\u003e$5,850\u003c\/strong\u003e for Repatha’s annual list price, a \u003cstrong\u003e$2,000\u003c\/strong\u003e Medicare Part D out-of-pocket cap in 2025, and IRA-selected drug reductions of \u003cstrong\u003e38%\u003c\/strong\u003e to \u003cstrong\u003e79%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePremium pricing fits specialty biologics\u003c\/strong\u003e. Amgen’s pricing power comes from drugs used for chronic, severe, or high-cost conditions, where access depends on payer coverage more than retail shopping. Repatha’s annual list price was reduced from \u003cstrong\u003e$14,100\u003c\/strong\u003e to \u003cstrong\u003e$5,850\u003c\/strong\u003e, a \u003cstrong\u003e58.5%\u003c\/strong\u003e cut, which shows how the Company can lower headline price while keeping a premium position. That kind of move helps preserve volume when payers control formulary access.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePricing item\u003c\/th\u003e\n\u003cth\u003eReal-life number\u003c\/th\u003e\n\u003cth\u003ePrice impact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepatha annual list price after reduction\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5,850\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePremium specialty-drug level\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepatha annual list price before reduction\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14,100\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eShows a \u003cstrong\u003e58.5%\u003c\/strong\u003e cut\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOtezla acquisition price\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.4B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRaised the need for durable net pricing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHorizon acquisition price per share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$116.50\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCash offer used to add specialty assets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHorizon acquisition equity value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$27.8B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eShows scale of portfolio expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare Part D out-of-pocket cap in 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eChanges patient affordability\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirst IRA negotiation cycle\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10\u003c\/strong\u003e drugs\u003c\/td\u003e\n\u003ctd\u003eSignals future government price pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIRA selected-drug reductions\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e38%\u003c\/strong\u003e to \u003cstrong\u003e79%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSets a ceiling on negotiated prices\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEffective date for first negotiated prices\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJan. 1, 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAffects forward pricing expectations in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRebates and contracting affect net realized price\u003c\/strong\u003e. Amgen does not keep the list price on most U.S. prescription sales. Rebates, chargebacks, discounts, and patient support reduce gross price to net price. The gap matters because a \u003cstrong\u003e$14,100\u003c\/strong\u003e list price is not the same as the amount Amgen actually collects after payer contracting. In pricing terms, this is the difference between headline price and realized price, and it is one of the main reasons premium biologics can still face margin pressure.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBiosimilar competition pressures mature-brand pricing\u003c\/strong\u003e. Mature products lose pricing power once biosimilars enter the market, because payers can demand lower rebates or switch volume to cheaper alternatives. Amgen’s own portfolio response included the \u003cstrong\u003e2019\u003c\/strong\u003e Otezla acquisition for \u003cstrong\u003e$13.4B\u003c\/strong\u003e and the \u003cstrong\u003e2023\u003c\/strong\u003e Horizon Therapeutics acquisition for \u003cstrong\u003e$27.8B\u003c\/strong\u003e. Those deals widened the mix away from older products that face sharper erosion. The timing also matters: the Horizon deal closed on \u003cstrong\u003eOct. 6, 2023\u003c\/strong\u003e, giving Amgen additional assets before the 2025 pricing reset in U.S. government programs.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2019\u003c\/strong\u003e: Otezla acquired for \u003cstrong\u003e$13.4B\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2023\u003c\/strong\u003e: Horizon Therapeutics acquired for \u003cstrong\u003e$27.8B\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOct. 6, 2023\u003c\/strong\u003e: Horizon transaction completed\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2025\u003c\/strong\u003e: Medicare Part D out-of-pocket cap set at \u003cstrong\u003e$2,000\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e10\u003c\/strong\u003e drugs in the first IRA negotiation cycle\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e38%\u003c\/strong\u003e to \u003cstrong\u003e79%\u003c\/strong\u003e negotiated reductions on selected drugs\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eIRA Medicare price setting hit Otezla in 2025\u003c\/strong\u003e. The measurable 2025 change was the Medicare Part D structure, not a public Amgen list-price announcement tied to Otezla. The most relevant numeric effect is the \u003cstrong\u003e$2,000\u003c\/strong\u003e annual out-of-pocket cap, which changes patient affordability for Part D therapies and can support demand retention in chronic oral treatment categories. The next price-pressure step is the negotiated-price framework, with first-cycle reductions of \u003cstrong\u003e38%\u003c\/strong\u003e to \u003cstrong\u003e79%\u003c\/strong\u003e and effective prices starting \u003cstrong\u003eJan. 1, 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePortfolio mix helps sustain margins and cash flow\u003c\/strong\u003e. Amgen’s pricing mix is stronger when premium biologics, newer launches, and acquired specialty assets offset lower-priced mature brands. The \u003cstrong\u003e$13.4B\u003c\/strong\u003e Otezla deal and the \u003cstrong\u003e$27.8B\u003c\/strong\u003e Horizon deal show a willingness to spend at scale to protect future pricing power. That matters because portfolio diversification reduces dependence on any single brand facing rebate pressure, biosimilar erosion, or Medicare price setting.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44602198622357,"sku":"amgn-marketing-mix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/amgn-marketing-mix.png?v=1740145942","url":"https:\/\/dcf-analysis.com\/products\/amgn-marketing-mix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}